Adrenal and pituitary functions during long-term topical steroid therapy.
D015068:17-Ketosteroids / Q000652:urine; D000287:Administration, Topical; D000309:Adrenal Insufficiency / Q000139:chemically induced*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D001623:Betamethasone / Q000009:adverse effects*; D002087:Butyrates; D004357:Drug Synergism; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007018:Hypopituitarism / Q000139:chemically induced*; D008797:Metyrapone; D008875:Middle Aged; D009779:Occlusive Dressings; D009824:Ointments; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000009:adverse effects*; D014631:Valerates
D015068:17-Ketosteroids; D000893:Anti-Inflammatory Agents; D002087:Butyrates; D009824:Ointments; D014631:Valerates; D001623:Betamethasone; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone; D008797:Metyrapone